注册
登录
全国服务热线：
18086415513
赛培新增产品文献：人IFN-γ，IL-10，IL-4，IgE ELISA试剂盒
发布时间：2022-04-08 11:17:54
布地奈德鼻喷雾剂治疗过敏性鼻炎患者的临床效果及 不良反应发生情况
牛艳，申江江 *，柳林整 （榆林市第一医院，陕西 榆林，719000） 摘要：目的 探究布地奈德鼻喷雾剂治疗过敏性鼻炎患者的临床效果及不良反应发生情况。方法 以 2018 年 6 月至 2020 年 1 月收治的 100 例过敏性鼻炎患者作为研究对象，根据单双号随机化法将其分为对照组与试验组，各 50例。 对照组给予氯雷他定治疗，试验组给予氯雷他定联合布地奈德鼻喷雾剂治疗。比较两组的治疗效果、症状改善时 间、炎症因子、IgE 水平、不良反应发生情况。结果 试验组的治疗总有效率为 98.00%，高于对照组的 82.00%（P<0.05）。 试验组的鼻痒、喷嚏、流涕、鼻塞改善时间均短于对照组（P<0.05）。治疗后，两组的 IFN-γ、IL-10 水平均高于治疗 前，IL-4、IgE 水平低于治疗前，且试验组优于对照组（P<0.05）。两组的不良反应总发生率比较，差异无统计学意义 （P>0.05）。结论 布地奈德鼻喷雾剂治疗过敏性鼻炎患者的临床效果显著，可缩短症状改善时间，改善炎症因子以 及 IgE 水平，且不会增加不良反应发生率。 关键词：布地奈德鼻喷雾剂；氯雷他定；过敏性鼻炎；不良反应 中图分类号： R765.21 文献标志码： A 文章编号： 2096-1413(2022)06-0034-03
Clinical effect and adverse reactions of budesonide nasal spray in the treatment of patients with allergic rhinitis
NIU Yan, SHEN Jiangjiang * , LIU Linzheng (the First Hospital of Yulin, Yulin 719000, China) ABSTRACT: Objective To investigate the clinical effect and adverse reactions of budesonide nasal spray in the treatment of patients with allergic rhinitis. Methods A total of 100 patients with allergic rhinitis admitted from June 2018 to January 2020 were taken as the research objects, and the patients were divided into control group and experimental group according to the single and even number randomization method, with 50 cases in each group. The control group was treated with loratadine, and the experimental group was treated with loratadine combined with budesonide nasal spray. The treatment effect, symptom improvement time, inflammatory factors and IgE levels and adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experimental group was 98.00% , which was higher than 82.00% in the control group (P<0.05). The improvement time of nasal itching, sneezing, runny nose and nasal congestion in the experimental group were shorter than those in the control group (P<0.05). After treatment, the levels of IFN-γ and IL-10 in the two groups were higher than those before treatment, the levels of IL -4 and IgE were lower than those before treatment, and those in the experimental group were better than the control group (P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Budesonide nasal spray in the treatment of patients with allergic rhinitis has a significant clinical effect, it can shorten the symptom improvement time, improve inflammatory factors and IgE levels, and will not increase the incidence of adverse reactions. KEYWORDS: budesonide nasal spray; loratadine; allergic rhinitis; adverse reactions
布地奈德鼻喷雾剂治疗过敏性...临床效果及不良反应发生情况_牛艳.pdf
